LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate ...Middle East

Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

Hence then, the article about lcmc3 neoadjuvant atezolizumab safe meets primary endpoint of pathologic response rate was published today ( Saturday 30/01/2021 - 06:31 PM ) and is available on ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( LCMC3: Neoadjuvant atezolizumab safe, meets primary endpoint of pathologic response rate )

Also on site :

• Ukraine will try “to get some concessions” from Trump at meeting
• Numbrix 9 - December 28
• Getting hired in 2026 is all about your ‘microcredentials’ says CEO of $1.3 billion learning platform—this is what he tells Gen Z to focus on